Sarcoma Alliance for Research through Collaboration

Quick facts

Phase 2 pipeline

• Bezuclastinib in combination with sunitinib · Oncology
  Bezuclastinib is a tyrosine kinase inhibitor that targets KIT and PDGFRα, and in combination with sunitinib, it is used to treat gastrointestinal stromal tumors (GIST).
• gemcitabine, docetaxel, doxorubicin

Competitive intelligence

For the full portfolio CI brief — phase mix, recent regulatory actions, upcoming PDUFA dates, patent timeline, class-overlap with competitors:

• Sarcoma Alliance for Research through Collaboration portfolio CI brief
• Sarcoma Alliance for Research through Collaboration pipeline updates RSS